Episode Summary
Executive Summary: The episode explains how pharmaceutical brand names are created, why they sound strange, and why that oddity is often deliberate. Naming firms like Brand Institute use research, linguistic constraints, FDA rules, and creative intuition to make names memorable, distinct, safe, and globally trademarkable—sometimes even poetic.
Main Topics: Why drug names sound unusual (Priority: 5/5): The show opens by mocking the surreal, almost sci-fi quality of pharmaceutical ads, then asks whether that weirdness is accidental or intentional. The answer: it is often the result of strict naming constraints and strategic design. How pharmaceutical naming actually works (Priority: 5/5): Scott Piergrossi of Brand Institute describes a rigorous process: client briefing, hundreds of candidate names, internal filtering, and iterative testing. Most names never reach approval, and many client preferences are discarded. Sources of name inspiration (Priority: 4/5): Name creators draw from many places: language dictionaries, word fragments, scientific mechanisms, abstract marketing ideas, and even AI tools. The goal is to craft names that suggest benefit without making explicit claims. FDA rules and safety constraints (Priority: 5/5): The FDA prohibits names that overpromise or too closely resemble existing drugs. Names must avoid misleading efficacy claims and reduce look-alike/sound-alike errors, which can contribute to medication mistakes and deaths. The poetry of naming (Priority: 4/5): Arlene Tech argues that naming is not just branding but a musical, poetic practice. She emphasizes sound, rhythm, and emotional resonance, saying the best names 'sing' and feel natural in speech. Viagra, Prozac, and the evolution of blockbuster names (Priority: 5/5): The episode traces the rise of modern pharma naming through landmark examples like Prozac and Viagra, showing how abstract yet memorable names helped redefine the industry’s naming standards. Visual and linguistic engineering (Priority: 4/5): Beyond sound, names are shaped by typography and visual silhouette—ascending/descending letters, distinctive shapes, and vowel/consonant patterns—to reduce confusion and improve recognizability.
Key Arguments: Drug names are not random nonsense; they are the product of a structured, highly regulated creative process that balances marketing, safety, and trademark demands. Brand Institute claims to create a majority of new drug names, and its work involves generating hundreds of candidates before narrowing to a few viable options. The FDA’s rules push names away from claims and toward ambiguity, which is why many names sound invented or abstract. Avoiding look-alike/sound-alike names is a patient-safety issue, not just a branding issue; naming can prevent fatal medication errors. Great drug names often work like poetry: they are chosen for sound, rhythm, and resonance as much as for meaning. Some names derive from the science of the drug, especially in oncology, where doctor-facing audiences value mechanism-based cues. Typography matters because visual similarity between handwritten or printed names can cause dangerous dispensing errors. The proliferation of new drugs has intensified the challenge of creating distinctive, globally approved names from a limited alphabet.
Data Points: Share of new drug names reportedly handled by Brand Institute: more than 75% - Scott Piergrossi says his company helps name the majority of new drugs and generic/non-proprietary names in a given year. Initial candidate names generated: 300 to 500 ideas - Brand Institute teams brainstorm a very large pool of names before filtering for client testing. Names typically retained from a client slide: about 2 out of 25 - Clients often reject most proposed names even when they requested easy pronunciation. FDA-approved therapeutic drugs in 1988: 17 - Used to illustrate the smaller scale of drug approvals when Prozac emerged. New drugs on the market last year: almost 50 - Shows the rising volume of approvals and the growing naming challenge. Drug duration example: 30 hours vs 24 hours - Tujeo was described as lasting longer than a similar insulin product, motivating a name associated with enduring companionship. Brand naming career span cited for Arlene Tech: 30+ years - She is presented as an experienced, early-generation pharmaceutical namer. Brand Institute tenure cited for Scott Piergrossi: more than 20 years - Establishes his long experience in pharmaceutical naming.
Pivotal Quotes: "underneath the noisiness of the names is not just a logic that you'd never guess is in operation." — Sean Cole: Explaining the central thesis that drug names follow hidden rules and logic. "It was like a mental orgasm. You get something that you know is good." — Arlene Tech: Describing the intense creative satisfaction of landing on a strong drug name. "The silhouette would have something that goes up someplace, something that goes down someplace." — Scott Piergrossi: Explaining how visual shape helps reduce confusion in drug-name approval.
Implications: Drug naming is a high-stakes blend of creativity, regulation, and safety. For listeners, it reframes funny-sounding ads as engineered language; for industry, it highlights growing pressure to create distinctive, globally safe names in an overcrowded market.